Valuation: Alvotech

Market Cap 124.46Cr 109.13Cr 100.59Cr 94Cr 176.6Cr 12TCr 180.26Cr 1.21TCr 467.84Cr 5.8TCr 467.37Cr 457.16Cr 20TCr P/E 2026 *
9.2x
P/E 2027 * 8.42x
Enterprise Value 234.36Cr 205.49Cr 189.42Cr 177.33Cr 332.52Cr 22TCr 339.43Cr 2.28TCr 880.93Cr 11TCr 880.04Cr 860.82Cr 38TCr EV / Sales 2026 *
3.55x
EV / Sales 2027 * 3.02x
Free-Float
41.72%
Yield 2026 *
-
Yield 2027 * -
1 day-5.95%
1 week-11.22%
Current month+3.57%
1 month+1.46%
3 months+11.90%
6 months-33.84%
Current year-32.16%
1 week 3.45
Extreme 3.45
3.77
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Free

Chief Executive Officer

1,17,271 0.0355%
01/04Buy

Founder

3,18,000 0.0963%
01/04Sell

Founder

3,18,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-5.95%-11.22%-61.93%-52.65% 124.46Cr
+0.62%+7.51%-4.78%+2.87% 4.62TCr
+2.19%+11.71%+393.31%+580.42% 3.87TCr
+2.53%+13.93%+21.38%-12.81% 3.19TCr
+1.65%+3.61%+16.04%+55.62% 3.11TCr
-4.16%-2.58%+8.94%+25.31% 2.38TCr
-0.32%+12.96% - - 1.62TCr
+1.37%+14.53%+69.64%+130.07% 1.51TCr
-0.32%+8.35%+13.80%+21.73% 1.37TCr
+3.63%+9.53%+103.97%+98.73% 1.34TCr
Average +0.15%+7.10%+62.26%+94.36% 2.31TCr
Weighted average by Cap. +0.89%+8.60%+88.09%+130.32%

Financials

2026 *2027 *
Net sales 66Cr 58Cr 53Cr 50Cr 94Cr 6.23TCr 96Cr 641.85Cr 248.36Cr 3.08TCr 248.11Cr 242.69Cr 11TCr 78Cr 69Cr 63Cr 59Cr 111.22Cr 7.39TCr 113.53Cr 761.46Cr 294.64Cr 3.65TCr 294.35Cr 287.92Cr 13TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.56TCr 24Cr 160.24Cr 62Cr 769.04Cr 62Cr 61Cr 2.67TCr 13Cr 12Cr 11Cr 10Cr 19Cr 1.26TCr 19Cr 130.22Cr 50Cr 624.98Cr 50Cr 49Cr 2.17TCr
Net Debt 109.9Cr 96Cr 89Cr 83Cr 155.93Cr 10TCr 159.17Cr 1.07TCr 413.09Cr 5.12TCr 412.67Cr 403.66Cr 18TCr 111.94Cr 98Cr 90Cr 85Cr 158.83Cr 11TCr 162.12Cr 1.09TCr 420.76Cr 5.22TCr 420.34Cr 411.16Cr 18TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26/26/26 $3.680 +5.75% 9,91,865
25/26/25 $3.480 -5.95% 10,88,290
24/26/24 $3.700 0.00% 7,87,083
23/26/23 $3.700 +1.37% 7,87,899
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.680USD
Average target price
13.83USD
Spread / Average Target
+275.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock